Thousands of plaintiffs across the country claiming in a federal lawsuit that Ozempic, Mounjaro and other popular drugs prescribed for diabetes and obesity harmed their health, and that the pharmaceutical companies that manufactured them failed to warn patients of their risks. The suit against two manufacturers, Novo Nordisk and Eli Lilly, was filed this year. It's in the discovery process and may go to trial in 2025. Central to the lawsuit is the claim that Ozempic caused plaintiffs' gastroparesis.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
